Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Drugs that Destabilize Microtubules

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Drugs that Stabilize Microtubules

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...

Antifungal Agents

Antifungal Agents

Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz·2026

Same author

Stereochemical Aspects in the Context of the Structure-Activity Relationship of Chlorido[<i>N</i>,<i>N</i>'-bis(chloro/bromosalicylidene)-1,2-diphenyl-1,2-diaminoethane]iron(III) Complexes.

Journal of medicinal chemistry·2026

Same author

Introduction of 1,3-diethyl-4,5-diphenyl-4,5-dihydro-1H-imidazol-2-ylidene as new ligand for the design of antitumor-active (NHC)gold(I) complexes: An approach to reduce ligand scrambling and to increase tumor cell selectivity.

European journal of medicinal chemistry·2025

Same author

Eradication of Therapy-Resistant Cancer Stem Cells by Novel Telmisartan Derivatives.

Journal of medicinal chemistry·2024

Same author

Circumventing Imatinib resistance in CML: Novel Telmisartan-based cell death modulators with improved activity and stability.

European journal of medicinal chemistry·2024

Same author

Transferrin Receptor-Mediated Cellular Uptake of Fluorinated Chlorido[<i>N</i>,<i>N</i>'-bis(salicylidene)-1,2-phenylenediamine]iron(III) Complexes.

ACS omega·2024

Search research articles

Related Experiment Videos

Bivalent bendamustine and melphalan derivatives as anticancer agents.

Ana Maria Scutaru¹, Maxi Wenzel, Ronald Gust

¹Institute of Pharmacy, Freie Universität Berlin, Königin Luise Str. 2+4, 14195 Berlin, Germany.

European Journal of Medicinal Chemistry

|March 5, 2011

Summary

New bivalent conjugates of bendamustine and melphalan showed increased cytotoxicity against breast cancer cell lines. These novel drug delivery systems enhance antitumor potency and selectivity for potential cancer therapies.

Related Experiment Videos

Area of Science:

Medicinal Chemistry
Oncology
Drug Delivery Systems

Background:

Bendamustine and melphalan are alkylating agents used in cancer treatment.
Improving antitumor potency and tumor selectivity of these agents is crucial.

Purpose of the Study:

To synthesize and evaluate novel bivalent conjugates of bendamustine and melphalan.
To assess the in vitro cytotoxicity of these derivatives against breast cancer cell lines.

Main Methods:

Synthesis of bivalent bendamustine and melphalan derivatives linked by diamines of varying chain lengths.
In vitro cytotoxicity assays using human MCF-7 and MDA-MB-231 breast cancer cell lines.
Concentration-dependent evaluation of cytotoxic effects.

Main Results:

Novel bivalent conjugates demonstrated increased cytotoxicity compared to parent drugs.
Cytotoxicity varied with the length of the diamine linker.
Enhanced cytotoxic effects were observed in both MCF-7 and MDA-MB-231 cell lines.

Conclusions:

Bivalent drug conjugates represent a promising strategy for enhancing the efficacy of bendamustine and melphalan.
The developed conjugates exhibit improved antitumor activity and selectivity.
These findings support further investigation of bivalent drug systems in cancer therapy.